Contact Info

Biography

Website: rileyimpactlab.com

Education:
Post-Doctoral, Department of Bioengineering, University of Pennsylvania
Ph.D., Department of Biomedical Engineering, University of Delaware
B.S., Department of Civil and Environmental Engineering, Rowan University

Impactful Research Areas:
Health
    Biomedical
Sustainability
    Sustainable Materials & Processes

Research Expertise:
Drug delivery, Nanotechnology, Prenatal Therapy, Gynecological and Pediatric Cancer Therapy                                                                                                                            
The Riley lab is at the interface of engineering, nanotechnology, and medicine to develop drug delivery platforms to treat disease with a focus on women’s health. We are interested in studying how the nanoparticle chemical composition and physicochemical properties influence their biodistribution and delivery to tissues and cells of interest, and we use these technologies to study and treat gynecological cancers and pregnancy-related conditions.

Recent Publications:
Riley RS, Kashyap M, Billingsley MM, White B, Alameh MG, Bose S, Zoltick PW, Li H, Zhang R, Cheng AY, Weissman D, Peranteau W, Mitchell MJ. Lipid Nanoparticle- Mediated mRNA Delivery to Fetuses In Utero (2021). Science Advances. 7:eaba1028.

Figueroa-Espada C, Hofbauer S, Mitchell MJ, and Riley RS. Exploiting the Placenta for Nanoparticle-Mediated Drug Delivery During Pregnancy (2020). Advanced Drug Delivery Reviews. S0169-409X(20)30130-7.

Riley RS, June C, Langer R, Mitchell M. Delivery Technologies for Cancer Immunotherapies: Challenges and Opportunities (2018). Nature Reviews Drug Discovery. 18(3), pp 175-196.                           

Riley RS, Dang M, Billingsley MM, Abraham B, Gundlach, L, Day ES (2018). Evaluating the Mechanisms of Light-Triggered siRNA Release from Nanoshells for Temporal Control Over Gene Regulation. Nano Letters. DOI: 10.1021/acs.nanlett.8b00681.

Riley RS, Day ES (2017). Frizzled7 antibody-functionalized nanoshells enable multivalent binding for enhanced Wnt signaling inhibition in Triple Negative Breast Cancer cells. Small. 13, 1700544.